PTCT Ptc Therapeutics Inc

Price (delayed)

$41.22

Market cap

$2.9B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.69

Enterprise value

$3.29B

Highlights
The quick ratio rose by 45% year-on-year
Ptc Therapeutics's revenue has increased by 34% YoY and by 13% from the previous quarter
The company's debt has surged by 71% YoY and by 28% QoQ
The net income has plunged by 55% YoY and by 3.6% from the previous quarter

Key stats

What are the main financial stats of PTCT
Market
Shares outstanding
70.46M
Market cap
$2.9B
Enterprise value
$3.29B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.91
Price to sales (P/S)
6.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.65
Earnings
Revenue
$430.45M
EBIT
-$348.79M
EBITDA
-$252.99M
Free cash flow
-$230.16M
Per share
EPS
-$6.69
Free cash flow per share
-$3.28
Book value per share
$4.16
Revenue per share
$6.13
TBVPS
$18.76
Balance sheet
Total assets
$2.11B
Total liabilities
$1.82B
Debt
$536.98M
Equity
$292.58M
Working capital
$871.42M
Liquidity
Debt to equity
1.84
Current ratio
4.47
Quick ratio
4.31
Net debt/EBITDA
-1.54
Margins
EBITDA margin
-58.8%
Gross margin
94.4%
Net margin
-105.5%
Operating margin
-96.3%
Efficiency
Return on assets
-22.8%
Return on equity
-97.8%
Return on invested capital
-30.5%
Return on capital employed
-18.7%
Return on sales
-81%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PTCT stock price

How has the Ptc Therapeutics stock price performed over time
Intraday
-2.04%
1 week
-4.52%
1 month
-5.07%
1 year
-13.8%
YTD
-32.46%
QTD
-2.48%

Financial performance

How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$430.45M
Gross profit
$406.49M
Operating income
-$414.45M
Net income
-$454.12M
Gross margin
94.4%
Net margin
-105.5%
The company's operating income has shrunk by 75% YoY
The net income has plunged by 55% YoY and by 3.6% from the previous quarter
Ptc Therapeutics's revenue has increased by 34% YoY and by 13% from the previous quarter
PTCT's gross profit is up by 32% YoY and by 12% QoQ

Growth

What is Ptc Therapeutics's growth rate over time

Valuation

What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
9.91
P/S
6.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.65
The EPS is down by 37% year-on-year
PTCT's P/B is 84% above its 5-year quarterly average of 5.4 and 25% above its last 4 quarters average of 7.9
Ptc Therapeutics's equity has decreased by 45% YoY and by 39% QoQ
Ptc Therapeutics's revenue has increased by 34% YoY and by 13% from the previous quarter
The price to sales (P/S) is 29% lower than the last 4 quarters average of 9.4 and 5% lower than the 5-year quarterly average of 7.1

Efficiency

How efficient is Ptc Therapeutics business performance
The return on equity has dropped by 90% year-on-year and by 17% since the previous quarter
The ROIC has grown by 37% YoY and by 15% from the previous quarter
Ptc Therapeutics's ROA has decreased by 19% YoY but it has increased by 3.4% from the previous quarter
The ROS is up by 11% since the previous quarter

Dividends

What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTCT.

Financial health

How did Ptc Therapeutics financials performed over time
The total assets is 16% more than the total liabilities
PTCT's total liabilities has surged by 79% year-on-year and by 5% since the previous quarter
The quick ratio rose by 45% year-on-year
The company's debt is 84% higher than its equity
PTCT's debt to equity has surged by 111% since the previous quarter
The company's debt has surged by 71% YoY and by 28% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.